Sonoma Biotherapeutics rakes in Series A

South San Francisco and Seattle-based Sonoma Biotherapeutics, a developer of regulatory T-cell therapies for autoimmune and degenerative diseases, has raised $30 million from investors in its Series A financing, bringing the total to $70 million.